THERAPY DOSSIER · th-ad994c46554d

Allogeneic bone marrow derived mesenchymal stromal cells (mononuclear fraction, passages 8 and 9)

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Wound
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 3

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT01586312 ↗PHASE1/PHASE2completed

Treatment of Knee Osteoarthritis With Allogenic Mesenchymal Stem Cells (MSV)

Knee Osteoarthritis

Enrolment: 30 · Results not recorded

NCT01686139 ↗PHASE1unknown

Allogeneic Bone Marrow Derived Mesenchymal Stromal Cells (ABMD-MSC) for Diabetic Foot Complications

Diabetic Foot Ulcer

Enrolment: 12 · Results not recorded

NCT02150551 ↗PHASE1completed

Safety of Allogeneic Bone Marrow-derived Mesenchymal Stromal Cells in Pediatric IBD

Inflammatory Bowel Diseases

Enrolment: 1 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 29889447 ↗2016Reported benefit

IMMUNOMODULATORY EFFECT OF ALLOGENEIC MESENCHYMAL STEM CELLS OF RATS.

RatWoundWistar3.5 x 10^6 cells/ml given twice, or 5.0 x 10^6 cells/mlAdministered on day 3 and/or day 7 after surgery

Model: Surgical wound of the glandular stomach

Allogeneic bone marrow mesenchymal stromal cells lowered pro-inflammatory mediators, raised IL-4 and improved healing quality of surgical gastric wounds.

Extraction: extract · Supplied extraction confidence: 0.45. Machine-extracted fields require source verification.

Loading the evidence…